Biotech
Ollin Biosciences
Ollin Biosciences raises $100M Series A at $500M valuation
$100M
Total Raised
Series A
Latest Round
2022
Founded
70+
Employees
Austin, TX
1 min read
Quick Facts
Valuation
$500M
Latest Round Size
$100M
Latest Round Date
September 2025
Ollin Biosciences: Series A Funding Round
Ollin Biosciences has successfully raised $100M in Series A funding, reaching a valuation of $500M.
Company Overview
Clinical-stage company for vision-threatening disease therapies
Funding Details
The Series A round was led by Deerfield Management, with participation from ARCH Venture Partners.
Company Information
- Headquarters: Austin, TX
- Founded: 2022
- Employees: 70+
- Category: Biotech
Investment
Ollin Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Deerfield Management: Verified investor in Series A
- ARCH Venture Partners: Verified investor in Series A
Key Investors
Deerfield Management
Lead Investor
Verified investor in Series A
ARCH Venture Partners
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M